Roberto Marchioli, M.D ., Guido Finazzi, M.D., Giorgina Specchia, M.D., Rossella Cacciola, M.D., Ph.D., Riccardo Cavazzina, Sc.D., Daniela Cilloni, M.D., Ph.D., Valerio De Stefano, M.D., Elena Elli, M.D., Alessandra Iurlo, M.D., Ph.D., Roberto Latagliata, M.D., Francesca Lunghi, M.D., Monia Lunghi, M.D., Rosa Maria Marfisi, M.S., Pellegrino Musto, M.D., Arianna Masciulli, M.D., Ph.D., Caterina Musolino, M.D., Ph.D., Nicola Cascavilla, M.D., Giovanni Quarta, M.D., Maria Luigia Randi, M.D., Davide Rapezzi, M.D., Marco Ruggeri, M.D., Elisa Rumi, M.D., Anna Rita Scortechini, M.D., Simone Santini, M.D., Marco Scarano, Sc.D., Sergio Siragusa, M.D., Antonio Spadea, M.D., Ph.D., Alessia Tieghi, M.D., Emanuele Angelucci, M.D., Giuseppe Visani, M.D., Alessandro Maria Vannucchi, M.D., and Tiziano Barbui, M.D.

The most common reason for discontinuation of typical medical therapy was insufficient effectiveness . There was no significant difference between your two groups in the frequency of serious adverse events . There was one loss of life in the levonorgestrel-IUS group; the cause of death was documented by the coroner as inconclusive, and the levonorgestrel-IUS had not been in situ. Severe adverse reasons and occasions for discontinuing therapy are summarized in Tables S2 and S3, respectively, in the Supplementary Appendix. Primary Outcome Total ratings on the MMAS improved considerably in both organizations at six months and at 12 months and 2 years, as compared with baseline scores , but improvements in these ratings were significantly greater among women assigned to levonorgestrel-IUS than among those assigned to normal treatment .